Tao Liu

Associate Professor Tao Liu is a prominent cancer researcher at the Children's Cancer Institute, which operates within the Lowy Cancer Research Centre at the University of New South Wales Australia (UNSW Australia). His work focuses on understanding the molecular mechanisms of cancer development and identifying novel therapeutic targets through epigenetic regulation.

Dr. Liu holds qualifications including BMed, MMed, and PhD, which have established his foundation in medical science and research methodology. His educational background has prepared him for his current research in oncology and molecular biology.

Dr. Liu's research program centers on:

• Transcriptional modulation of oncogene and tumour suppressor gene expression
• Epigenetic mechanisms including histone modifications and RNA methylation
• Role of BET bromodomain proteins and super-enhancers in cancer
• CDK7 and other kinase inhibitors for cancer therapy
• Myc oncoprotein regulation and stability mechanisms
• Long noncoding RNAs as therapeutic targets

With 132 journal articles and numerous conference contributions to his name, Dr. Liu has established himself as a significant contributor to cancer research. His work primarily investigates how epigenetic regulators control gene expression in cancer cells and how these mechanisms can be targeted therapeutically.

Dr. Liu serves in multiple editorial capacities including Specialty Chief Editor for Frontiers in Oncology and Associate Editor for Frontiers in Genetics. He is an active member of the American Association for Cancer Research and serves on the Advisory Board of the international Advances in Neuroblastoma Research Association.

Dr. Liu currently supervises PhD and Honours students in cancer research and has secured substantial funding from prestigious organizations including the National Institutes of Health USA, US Department of Defense, National Health & Medical Research Council, Cancer Council NSW, Tour de Cure, and Neuroblastoma Australia.

His laboratory at the Children's Cancer Institute within the Lowy Cancer Research Centre focuses on translating basic molecular discoveries into potential cancer therapies, with particular emphasis on epigenetic drug targets and RNA-based therapeutics.